middle.news
CSL Unveils Bold Transformation with $500m Cost Cuts and Seqirus Demerger
7:49am on Tuesday 19th of August, 2025 AEST
•
Healthcare
Read Story
CSL Unveils Bold Transformation with $500m Cost Cuts and Seqirus Demerger
7:49am on Tuesday 19th of August, 2025 AEST
Key Points
FY25 revenue rises 5% to $15.6 billion, NPAT up 17%
Targeting $500 million annual cost savings by FY28 with up to 15% workforce reduction
CSL Seqirus to be demerged as a separate ASX-listed vaccine leader in FY26
Multi-year share buyback program to restart in FY26, beginning with A$750 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE